Johnny Hu is a venture capital investor at Menlo Ventures who developed CRISPR gene-editing technologies during his Harvard Ph.D. that were later licensed by Editas Medicine and Beam Therapeutics, giving him direct lab experience before transitioning to investing. He focuses on both new medicines and AI-driven biotech companies, maintaining active connections to frontier protein design communities through his published research in Nature and ongoing engagement with leaders in the field. Johnny Hu is a venture capital investor at Menlo Ventures who developed CRISPR gene-editing technologies during his Harvard Ph.D. that were later licensed by Editas Medicine and Beam Therapeutics, giving him direct lab experience before transitioning to investing. He focuses on both new medicines and AI-driven biotech companies, maintaining active connections to frontier protein design communities through his published research in Nature and ongoing engagement with leaders in the field.